New Market Research Report: Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013
Global Markets Direct's, 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL). Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using data and information sourced...
View full press release